Concomitant Vaccine Composition for Robust T-Cell Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine strategies require multiple administrations to stimulate both CD4+ and CD8+ T-cell responses, which can be burdensome and may lead to adverse reactions due to immunity against viral vectors, limiting the effectiveness of booster shots, especially in mass immunization programs and for pathogens like HIV.
Innovation Solution
A vaccine composition comprising immunogenic polypeptides, adenoviral vectors encoding these polypeptides, and an adjuvant administered concomitantly to stimulate CD4+ and CD8+ T-cell responses without the need for complex prime-boost schedules, thereby minimizing viral vector doses and enhancing immune response intensity and persistence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple prime-boost administrations are used to stimulate both CD4+ and CD8+ T-cell responses, then immune response completeness is improved, but vaccine complexity and burden increase
Solution Approach 1:
The patent combines multiple vaccine components (adenoviral vector encoding antigen, adjuvant, and immunomodulatory molecules) into a single composite vaccine formulation that can elicit both CD4+ and CD8+ T-cell responses simultaneously, eliminating the need for separate prime-boost administrations
2Reliability
If repeated booster vaccinations are administered to maintain immune response, then immune memory is improved, but adverse reactions increase
Solution Approach 1:
The vaccine incorporates adjuvants and immunomodulatory molecules that预先 activate and prime the immune system, creating a heightened state of immune readiness that enhances the durability of immune memory from the first administration and reduces the need for subsequent boosters
Solution Approach 2:
The patent modifies immune response parameters by using specific adjuvants and immunomodulatory molecules that alter the quality and duration of T-cell responses, creating a more persistent immune memory that lasts without requiring repeated vaccinations
3Power
If viral vector-based vaccines are used for booster shots, then immune response intensity is improved, but vector immunity limits effectiveness
Solution Approach 1:
The patent divides the vaccine strategy into distinct components: the adenoviral vector for initial priming, followed by alternative booster approaches using different modalities (protein subunit vaccines, mRNA vaccines, or viral vectored vaccines using different serotypes), thereby segmenting the immunization schedule to avoid vector immunity interference
Data Source
AI summary
The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants.